Related Experiment Video
Updated: Jul 18, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
Published on: March 16, 2018
Interleukin-1beta up-regulates inducible nitric oxide by way of phosphoinositide 3-kinase-dependent in a cochlear
1Department of Otolaryngology, School of Medicine, Keimyung University, Daegu, South Korea. entnamsi@dsmc.or.kr
Insights
Interleukin (IL)-1beta significantly increases inducible nitric oxide synthase (iNOS) in cochlear cells via transcription and PI3K signaling. This finding is crucial for understanding inflammatory responses in the cochlea.
Area of Science:
- Otolaryngology
- Immunology
- Molecular Biology
Background:
- Interleukin (IL)-1beta is a key pro-inflammatory cytokine.
- Inducible nitric oxide synthase (iNOS) plays a role in inflammatory processes within the cochlea.
Purpose of the Study:
- To investigate the effect of IL-1beta on iNOS expression in cochlear cells.
- To elucidate the molecular and signaling mechanisms underlying IL-1beta-induced iNOS expression.
Main Methods:
- HEI-OC1 cells were treated with IL-1beta and specific pathway inhibitors (PI3K, JNK, ERK, p38 MAPK).
- iNOS protein and mRNA levels were quantified using Western blot and RT-PCR.
- Luciferase assays assessed iNOS transcriptional activity.
Main Results:
- IL-1beta dose-dependently increased iNOS expression and nitric oxide (NO) production.
- Inhibition of the phosphoinositide 3-kinase (PI3K) pathway significantly reduced IL-1beta-induced iNOS expression.
- Inhibition of JNK and ERK pathways did not affect IL-1beta-induced iNOS expression.
Conclusions:
- IL-1beta strongly induces iNOS expression and NO production in cochlear cells.
- The induction mechanism involves increased iNOS transcription and activation of the PI3K signaling pathway.
Objective:
To investigate the effect of interleukin (IL)-1beta on inducible nitric oxide (iNOS) expression in cochlea and the molecular and signaling mechanisms involved.
Materials And Methods:
House Ear Institute-Organ of Corti 1 (HEI-OC1) cells were used and exposed to IL-1beta. Pharmacologic inhibitors such as PD98059 (an extracellular-regulated protein kinase [ERKs] inhibitor), SB203580 (a p38 mitogen-activated protein kinase [MAPK] inhibitor), SP600125 (a c-Jun N-terminal kinases [JNKs]) inhibitor), and LY294002 (an inhibitor of phosphoinositide 3-kinase [PI3 K]) were used to see the role of JNKs, ERKs, p38 MAPK, or PI3 K signaling pathway(s) in iNOS expression in response to IL-1beta in HEI-OC1 cells. Western blot and reverse-transcription polymerase chain reaction analyses were used to measure iNOS protein and mRNA expression, respectively. Luciferase assay was carried out to measure the transcription of iNOS by IL-1beta in HEI-OC1 cells.
Results:
Treatment of IL-1beta resulted in a concentration-dependent increase of iNOS protein and mRNA and NO production. One nanogram per milliliter of IL-1beta treatment for 4 to 8 hours was sufficient to highly induce iNOS. IL-1beta treatment also led to activation of JNKs, ERKs, and p70S6 K. Interestingly, pharmacologic inhibition of the PI3 K signaling pathway by LY294002 resulted in strong down-regulation of the IL-1beta-induced expressions of iNOS protein and mRNA. However, inhibition of JNKs and ERKs by SP29004 and PD98059, respectively, had no effect on the IL-1beta-induced iNOS expression.
Conclusions:
These results suggest that the pro-inflammatory cytokine IL-1beta strongly induces iNOS expression and NO production in HEI-OC1 cells, and the induction appears to be achieved by increased iNOS transcription and activation of PI3 K signaling pathway.
Related Concept Videos
Nitric Oxide Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
IP3/DAG Signaling Pathway
NF-kB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
